Bayer HealthCare Selects Tripos to Provide Drug Discovery Software For Its Global Enterprise
Tripos, Inc. and Bayer HealthCare AG have announced an agreement to deploy Tripos' proprietary discovery informatics software, SYBYL(R) and UNITY(R), globally across Bayer's drug discovery and development organization. Under the terms of the agreement, Tripos will provide Bayer with license rights to SYBYL and UNITY for its sites in Germany and the United States that are focused on the discovery and development of new therapeutics. Financial terms of the agreement were not disclosed.
The SYBYL computational chemistry and molecular modeling system is the heart of Tripos' discovery software offering, providing the fundamental components for research scientists to understand molecular structure and properties, with a special focus on the creation of new chemical entities. UNITY adds functionality to SYBYL with rapid, conformationally-flexible three-dimensional searching of chemical and biological databases.
"The seamless integration of cheminformatics, pharmacophore modeling and protein structure-based design tools offered by Tripos' software products will help us focus our synthesis efforts on promising compounds," said Dr. Hanno Wild, vice president for medicinal chemistry at Bayer HealthCare.
Dr. Alexander Hillisch, head of computational chemistry at Bayer HealthCare AG, added, "Tripos' ability to offer a complete computational chemistry suite, including sophisticated high-throughput docking programs on the Linux platform, was a critical factor in our choice."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Agkistrodon_bilineatus
Dade Behring and Tecan to co-market pre-analytical workstation
Schistosoma_japonicum

Two Group A Streptococcus genes linked to 'flesh-eating' bacterial infections
Entire T-cell receptor repertoire sequenced revealing extensive and unshared diversity

Uridine makes you hungry - Study on volunteers finds new regulator of food intake
Evotec extends ongoing collaboration with CHDI Foundation
List_of_subjects_in_Gray's_Anatomy:_VIII._The_Lymphatic_system

Innovative approach to treat autism spectrum disorders - University of Basel spin-off Translation-X receives Venture Kick funding
Resoimplant GmbH successfully closes third financing round - 2,54 Mil. Euro for the innovative medtech company from Regensburg, Bavaria
Roberto_Andorno
